Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
898 studies found for:    pharmacogenomics OR pharmacogenetics
Show Display Options
Rank Status Study
21 Recruiting LCI-NOS-PAIN-001: A Prospective, Pharmacogenomic-Driven Study of Pain Management in Oncology Outpatients
Condition: Malignant Tumor of Ill-defined Site
Intervention: Genetic: Pharmacogenomic Testing
22 Unknown  Validation of Pharmacogenetics Plus Drug Combination Guided Initial Tacrolimus Dosage in Renal Transplant Recipients
Condition: Renal Transplantation
Interventions: Other: drug (tacrolimus and SchE) and genetics;   Drug: tacrolimus
23 Recruiting Utility of PharmacoGenomics for Reducing Adverse Drug Effects
Condition: Genetics of Drug Metabolism
Intervention:
24 Unknown  Pharmacogenomics of Mood Stabilizer Response in Bipolar Disorder (PGBD)
Condition: Bipolar Affective Disorder
Intervention: Drug: Mood stabilizer treatment
25 Enrolling by invitation Integrating Pharmacogenetics In Clinical Care
Condition: Cardiovascular Disease
Intervention: Genetic: SLCO1B1 Genotype
26 Unknown  Pharmacogenomics Studies of Antidepressants
Conditions: Major Depressive Disorder;   Antidepressive Agents;   Pharmacogenetics;   Venlafaxine;   Fluoxetine
Interventions: Drug: Venlafaxine;   Drug: Fluoxetine
27 Completed Pharmacogenomics Validation for Imatinib in Chronic Myeloid Leukemia
Condition: Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Intervention:
28 Completed Pharmacogenetics of Warfarin in Puerto Ricans.
Conditions: Atrial Fibrillation;   Deep Vein Thrombosis;   Cardiac Valvular Insufficiency;   Antiphospholipid Syndrome;   Coagulopathy
Intervention:
29 Completed Pharmacogenomic of Atazanavir/Efavirenz (ATV/EFV)
Condition: HIV Infections
Intervention:
30 Completed Pharmacogenetic Testing Among Home Health Patients
Conditions: Adverse Drug Events;   Adverse Drug Reactions;   Drug Interaction Potentiation;   Drug Metabolism, Poor, CYP2D6-RELATED;   Drug Metabolism, Poor, CYP2C19-RELATED;   Cytochrome P450 Enzyme Deficiency;   Cytochrome P450 CYP2D6 Enzyme Deficiency;   Cytochrome P450 CYP2C9 Enzyme Deficiency;   Cytochrome P450 CYP2C19 Enzyme Deficiency;   Cytochrome P450 CYP3A Enzyme Deficiency;   Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant;   Poor Metabolizer Due to Cytochrome p450 CYP2C19 Variant;   Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant
Intervention: Genetic: Pharmacogenetic testing
31 Unknown  Pharmacogenomics of Anti-TNF (Anti-tumor Necrosis Factor) Treatment in Patients With Rheumatoid Arthritis
Condition: Rheumatoid Arthritis
Intervention:
32 Recruiting Development of Pharmacogenomic Method to Predict Antidepressant Responsiveness
Conditions: Depression;   Antidepressant Drug Adverse Reaction
Interventions: Drug: SSRI treated group;   Drug: non-SSRI treated group
33 Recruiting Clinical Study Evaluating Effects of Pharmacogenetic-guided vs Standard-of-Care Treatment on Depression and/or Anxiety
Conditions: Depression;   Anxiety
Intervention: Genetic: IDgenetix Neuropsychiatric Test Panel
34 Withdrawn Study Using Pharmacogenetics to Select Treatment for Head and Neck Cancer
Condition: Head and Neck Cancer
Interventions: Drug: Cisplatin;   Drug: Cetuximab
35 Recruiting The Pharmacogenetics of Optimal Warfarin Therapy in Chinese Patients After Heart Valve Replacement.
Conditions: Heart Valve Disease;   Older Than 18-years-old;   Without Any Liver or Kidney Diseases
Intervention: Genetic: CYP2C9;VKORC1
36 Completed EFV Pharmacokinetics & Pharmacogenomics in Older HIV-infected Patients
Condition: HIV Infection
Intervention: Drug: Efavirenz
37 Completed
Has Results
Personalized Medicine Interface Tool (PerMIT): Warfarin: A Trial Comparing Usual Care Warfarin Initiation to PerMIT Pharmacogenetic Guided Warfarin Therapy
Condition: Blood Clotting
Interventions: Genetic: warfarin pharmacogenetic dosing;   Drug: Warfarin
38 Completed Pharmacogenetics of Remifentanil in Patients With Hypertension Undergoing Cesarean Delivery Under General Anesthesia
Conditions: Pregnancy;   Cesarean Delivery;   General Anesthesia
Intervention: Drug: Remifentanil
39 Recruiting Standard of Care Versus Urine Testing With Selective PHarmacogenomics for Effective Drug and Dosing REgimens
Condition: Target Drug-related Adverse Events
Interventions: Other: Urine diagnostic testing as SOC, drug regimen changes per SOC;   Other: Urine diagnostic testing with selective PGx testing, drug regimen changes based on PGx test results
40 Active, not recruiting Prediction of Antidepressant Response Using Pharmacogenetics and Peripheral Lymphocytic Phenotype
Condition: Depression
Interventions: Drug: responders;   Drug: non-responders

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years